Pfizer released full phase 3 data showing its mRNA seasonal influenza vaccine candidate delivered 34.5% greater efficacy than a standard control vaccine in the pivotal study. The readout expands momentum for mRNA beyond COVID‑19 and underpins industry efforts to convert seasonal vaccines to mRNA platforms. Trial details released by the company indicate the benefit was measured across primary virologically confirmed endpoints; safety signals were consistent with expectations. For the biotech sector: success in large, routine vaccine markets would validate mRNA manufacturing scale and could accelerate commercial rollout plans for other mRNA seasonal products.